Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Tissue Cytokine IL-33 Modulates the Cytotoxic CD8 T Lymphocyte Activity During Nutrient Deprivation by Regulation of Lineage-Specific Differentiation Programs.

Dreis C, Ottenlinger FM, Putyrski M, Ernst A, Huhn M, Schmidt KG, Pfeilschifter JM, Radeke HH.

Front Immunol. 2019 Jul 24;10:1698. doi: 10.3389/fimmu.2019.01698. eCollection 2019.

2.

Sphingosine kinase 2 is a negative regulator of inflammatory macrophage activation.

Weigert A, von Knethen A, Thomas D, Faria I, Namgaladze D, Zezina E, Fuhrmann D, Petcherski A, Heringdorf DMZ, Radeke HH, Brüne B.

Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Sep;1864(9):1235-1246. doi: 10.1016/j.bbalip.2019.05.008. Epub 2019 May 23.

3.

A Comprehensive Assessment of Apigenin as an Antiproliferative, Proapoptotic, Antiangiogenic and Immunomodulatory Phytocompound.

Ghițu A, Schwiebs A, Radeke HH, Avram S, Zupko I, Bor A, Pavel IZ, Dehelean CA, Oprean C, Bojin F, Farcas C, Soica C, Duicu O, Danciu C.

Nutrients. 2019 Apr 16;11(4). pii: E858. doi: 10.3390/nu11040858.

4.

Cancer-induced inflammation and inflammation-induced cancer in colon: a role for S1P lyase.

Schwiebs A, Herrero San Juan M, Schmidt KG, Wiercinska E, Anlauf M, Ottenlinger F, Thomas D, Elwakeel E, Weigert A, Farin HF, Bonig H, Scholich K, Geisslinger G, Pfeilschifter JM, Radeke HH.

Oncogene. 2019 Jun;38(24):4788-4803. doi: 10.1038/s41388-019-0758-x. Epub 2019 Feb 28.

PMID:
30816345
5.

NoxO1 Controls Proliferation of Colon Epithelial Cells.

Moll F, Walter M, Rezende F, Helfinger V, Vasconez E, De Oliveira T, Greten FR, Olesch C, Weigert A, Radeke HH, Schröder K.

Front Immunol. 2018 May 8;9:973. doi: 10.3389/fimmu.2018.00973. eCollection 2018.

6.

Nuclear Translocation of SGPP-1 and Decrease of SGPL-1 Activity Contribute to Sphingolipid Rheostat Regulation of Inflammatory Dendritic Cells.

Schwiebs A, Thomas D, Kleuser B, Pfeilschifter JM, Radeke HH.

Mediators Inflamm. 2017;2017:5187368. doi: 10.1155/2017/5187368. Epub 2017 Dec 11.

7.

Biglycan, a novel trigger of Th1 and Th17 cell recruitment into the kidney.

Nastase MV, Zeng-Brouwers J, Beckmann J, Tredup C, Christen U, Radeke HH, Wygrecka M, Schaefer L.

Matrix Biol. 2018 Aug;68-69:293-317. doi: 10.1016/j.matbio.2017.12.002. Epub 2017 Dec 15.

PMID:
29253517
8.

Sphingosine-1-Phosphate Receptor 5 Modulates Early-Stage Processes during Fibrogenesis in a Mouse Model of Systemic Sclerosis: A Pilot Study.

Schmidt KG, Herrero San Juan M, Trautmann S, Berninger L, Schwiebs A, Ottenlinger FM, Thomas D, Zaucke F, Pfeilschifter JM, Radeke HH.

Front Immunol. 2017 Sep 29;8:1242. doi: 10.3389/fimmu.2017.01242. eCollection 2017.

9.

Immunopharmacological Activity of Betulin in Inflammation-associated Carcinogenesis.

Schwiebs A, Radeke HH.

Anticancer Agents Med Chem. 2018;18(5):645-651. doi: 10.2174/1871520617666171012124820. Review.

PMID:
29022515
10.

Management of inflammatory bowel disease-related anemia and iron deficiency with specific reference to the role of intravenous iron in current practice.

Stein J, Aksan A, Farrag K, Dignass A, Radeke HH.

Expert Opin Pharmacother. 2017 Nov;18(16):1721-1737. doi: 10.1080/14656566.2017.1391790. Epub 2017 Nov 5. Review.

PMID:
29019427
11.

Letter: the importance of dosing and baseline haemoglobin when establishing the relative efficacy of intravenous iron therapies-authors' reply.

Aksan A, Işık H, Radeke HH, Dignass A, Stein J.

Aliment Pharmacol Ther. 2017 Oct;46(7):705-706. doi: 10.1111/apt.14269. No abstract available.

12.

Letter: inconsistency in reporting of hypophosphataemia after intravenous iron-authors' reply.

Aksan A, Işık H, Radeke HH, Dignass A, Stein J.

Aliment Pharmacol Ther. 2017 Sep;46(6):643-644. doi: 10.1111/apt.14254. No abstract available.

13.

Editorial: which iron preparation for patients with IBD? Authors' reply.

Aksan A, Işık H, Radeke HH, Dignass A, Stein J.

Aliment Pharmacol Ther. 2017 Jul;46(2):195-196. doi: 10.1111/apt.14126. No abstract available.

14.

Ceramide synthase 2 deficiency aggravates AOM-DSS-induced colitis in mice: role of colon barrier integrity.

Oertel S, Scholich K, Weigert A, Thomas D, Schmetzer J, Trautmann S, Wegner MS, Radeke HH, Filmann N, Brüne B, Geisslinger G, Tegeder I, Grösch S.

Cell Mol Life Sci. 2017 Aug;74(16):3039-3055. doi: 10.1007/s00018-017-2518-9. Epub 2017 Apr 12.

PMID:
28405720
15.

Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease.

Aksan A, Işık H, Radeke HH, Dignass A, Stein J.

Aliment Pharmacol Ther. 2017 May;45(10):1303-1318. doi: 10.1111/apt.14043. Epub 2017 Mar 21. Review.

16.

Defective IL-23/IL-17 Axis Protects p47phox-/- Mice from Colon Cancer.

Richter C, Herrero San Juan M, Weigmann B, Bergis D, Dauber K, Muders MH, Baretton GB, Pfeilschifter JM, Bonig H, Brenner S, Radeke HH.

Front Immunol. 2017 Jan 27;8:44. doi: 10.3389/fimmu.2017.00044. eCollection 2017.

17.

High thioredoxin-1 levels in rheumatoid arthritis patients diminish binding and signalling of the monoclonal antibody Tregalizumab.

Heim K, Dälken B, Faust S, Rharbaoui F, Engling A, Wallmeier H, Dingermann T, Radeke HH, Schüttrumpf J, Gutscher M.

Clin Transl Immunology. 2016 Dec 23;5(12):e121. doi: 10.1038/cti.2016.69. eCollection 2016 Dec.

18.

Current evaluation and management of anemia in patients with inflammatory bowel disease.

Martin J, Radeke HH, Dignass A, Stein J.

Expert Rev Gastroenterol Hepatol. 2017 Jan;11(1):19-32. Epub 2016 Nov 29. Review.

PMID:
27885843
19.

Interferon-Beta Increases Plasma Ceramides of Specific Chain Length in Multiple Sclerosis Patients, Unlike Fingolimod or Natalizumab.

Ottenlinger FM, Mayer CA, Ferreirós N, Schreiber Y, Schwiebs A, Schmidt KG, Ackermann H, Pfeilschifter JM, Radeke HH.

Front Pharmacol. 2016 Nov 3;7:412. eCollection 2016.

20.

Activation-Induced Cell Death of Dendritic Cells Is Dependent on Sphingosine Kinase 1.

Schwiebs A, Friesen O, Katzy E, Ferreirós N, Pfeilschifter JM, Radeke HH.

Front Pharmacol. 2016 Apr 15;7:94. doi: 10.3389/fphar.2016.00094. eCollection 2016.

21.

High plasma sST2 levels in gastric cancer and their association with metastatic disease.

Bergis D, Kassis V, Radeke HH.

Cancer Biomark. 2016;16(1):117-25. doi: 10.3233/CBM-150547.

PMID:
26835712
22.

Fingolimod targeting protein phosphatase 2A differently affects IL-33 induced IL-2 and IFN-γ production in CD8(+) lymphocytes.

Ottenlinger F, Schwiebs A, Pfarr K, Wagner A, Grüner S, Mayer CA, Pfeilschifter JM, Radeke HH.

Eur J Immunol. 2016 Apr;46(4):941-51. doi: 10.1002/eji.201545805. Epub 2016 Jan 13.

23.

Increased Serum Levels of the IL-33 Neutralizing sST2 in Limited Cutaneous Systemic Sclerosis.

Wagner A, Köhm M, Nordin A, Svenungsson E, Pfeilschifter JM, Radeke HH.

Scand J Immunol. 2015 Sep;82(3):269-74. doi: 10.1111/sji.12317.

24.

MPGES-1-derived PGE2 suppresses CD80 expression on tumor-associated phagocytes to inhibit anti-tumor immune responses in breast cancer.

Olesch C, Sha W, Angioni C, Sha LK, Açaf E, Patrignani P, Jakobsson PJ, Radeke HH, Grösch S, Geisslinger G, von Knethen A, Weigert A, Brüne B.

Oncotarget. 2015 Apr 30;6(12):10284-96.

25.

Simultaneous and dose dependent melanoma cytotoxic and immune stimulatory activity of betulin.

Pfarr K, Danciu C, Arlt O, Neske C, Dehelean C, Pfeilschifter JM, Radeke HH.

PLoS One. 2015 Mar 10;10(3):e0118802. doi: 10.1371/journal.pone.0118802. eCollection 2015.

26.

Subcellular distribution of FTY720 and FTY720-phosphate in immune cells - another aspect of Fingolimod action relevant for therapeutic application.

Schröder M, Arlt O, Schmidt H, Huwiler A, Angioni C, Pfeilschifter JM, Schwiebs A, Radeke HH.

Biol Chem. 2015 Jun;396(6-7):795-802. doi: 10.1515/hsz-2014-0287.

27.

A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway.

Helling B, König M, Dälken B, Engling A, Krömer W, Heim K, Wallmeier H, Haas J, Wildemann B, Fritz B, Jonuleit H, Kubach J, Dingermann T, Radeke HH, Osterroth F, Uherek C, Czeloth N, Schüttrumpf J.

Immunol Cell Biol. 2015 Apr;93(4):396-405. doi: 10.1038/icb.2014.102. Epub 2014 Dec 16.

28.

Immunomodulatory effects of 25-hydroxyvitamin D3 on monocytic cell differentiation and influence of vitamin D3 polymorphisms in type 1 diabetes.

Mauf S, Penna-Martinez M, Jentzsch T, Ackermann H, Henrich D, Radeke HH, Brück P, Badenhoop K, Ramos-Lopez E.

J Steroid Biochem Mol Biol. 2015 Mar;147:17-23. doi: 10.1016/j.jsbmb.2014.11.001. Epub 2014 Nov 7.

PMID:
25448747
29.

Modulation of IL-33/ST2-TIR and TLR signalling pathway by fingolimod and analogues in immune cells.

Rüger K, Ottenlinger F, Schröder M, Zivković A, Stark H, Pfeilschifter JM, Radeke HH.

Scand J Immunol. 2014 Dec;80(6):398-407. doi: 10.1111/sji.12238.

30.

Sphingosine-1-phosphate modulates dendritic cell function: focus on non-migratory effects in vitro and in vivo.

Arlt O, Schwiebs A, Japtok L, Rüger K, Katzy E, Kleuser B, Radeke HH.

Cell Physiol Biochem. 2014;34(1):27-44. doi: 10.1159/000362982. Epub 2014 Jun 16. Review.

31.

Galectin-9 is a suppressor of T and B cells and predicts the immune modulatory potential of mesenchymal stromal cell preparations.

Ungerer C, Quade-Lyssy P, Radeke HH, Henschler R, Königs C, Köhl U, Seifried E, Schüttrumpf J.

Stem Cells Dev. 2014 Apr 1;23(7):755-66. doi: 10.1089/scd.2013.0335. Epub 2013 Nov 13.

32.

Response to comment on "CXCL9 causes heterologous desensitization of CXCL12-mediated memory T lymphocyte activation".

Giegold O, Ogrissek N, Radeke HH.

J Immunol. 2013 Jul 15;191(2):525-6. doi: 10.4049/jimmunol.1390037. No abstract available.

33.

High Serum Levels of the Interleukin-33 Receptor Soluble ST2 as a Negative Prognostic Factor in Hepatocellular Carcinoma.

Bergis D, Kassis V, Ranglack A, Koeberle V, Piiper A, Kronenberger B, Zeuzem S, Waidmann O, Radeke HH.

Transl Oncol. 2013 Jun 1;6(3):311-8. Print 2013 Jun.

34.

CXCL9 causes heterologous desensitization of CXCL12-mediated memory T lymphocyte activation.

Giegold O, Ogrissek N, Richter C, Schröder M, Herrero San Juan M, Pfeilschifter JM, Radeke HH.

J Immunol. 2013 Apr 1;190(7):3696-705. doi: 10.4049/jimmunol.1101293. Epub 2013 Feb 27.

35.

A rationally engineered anti-HIV peptide fusion inhibitor with greatly reduced immunogenicity.

Brauer F, Schmidt K, Zahn RC, Richter C, Radeke HH, Schmitz JE, von Laer D, Egerer L.

Antimicrob Agents Chemother. 2013 Feb;57(2):679-88. doi: 10.1128/AAC.01152-12. Epub 2012 Nov 12.

36.

Sphingosine 1-phosphate modulates antigen capture by murine Langerhans cells via the S1P2 receptor subtype.

Japtok L, Schaper K, Bäumer W, Radeke HH, Jeong SK, Kleuser B.

PLoS One. 2012;7(11):e49427. doi: 10.1371/journal.pone.0049427. Epub 2012 Nov 8.

37.

LC-MS/MS determination of FTY720 and FTY720-phosphate in murine intracellular compartments and human plasma.

Ferreirós N, Labocha S, Schröder M, Radeke HH, Geisslinger G.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Mar 1;887-888:122-7. doi: 10.1016/j.jchromb.2012.01.023. Epub 2012 Jan 30.

PMID:
22341683
38.

Selective glucocorticoid receptor agonists for the treatment of inflammatory bowel disease: studies in mice with acute trinitrobenzene sulfonic acid colitis.

Reuter KC, Grunwitz CR, Kaminski BM, Steinhilber D, Radeke HH, Stein J.

J Pharmacol Exp Ther. 2012 Apr;341(1):68-80. doi: 10.1124/jpet.111.183947. Epub 2012 Jan 10.

PMID:
22235147
39.

Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma.

Bihrer V, Waidmann O, Friedrich-Rust M, Forestier N, Susser S, Haupenthal J, Welker M, Shi Y, Peveling-Oberhag J, Polta A, von Wagner M, Radeke HH, Sarrazin C, Trojan J, Zeuzem S, Kronenberger B, Piiper A.

PLoS One. 2011;6(10):e26971. doi: 10.1371/journal.pone.0026971. Epub 2011 Oct 31.

40.

Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection.

Bihrer V, Friedrich-Rust M, Kronenberger B, Forestier N, Haupenthal J, Shi Y, Peveling-Oberhag J, Radeke HH, Sarrazin C, Herrmann E, Zeuzem S, Waidmann O, Piiper A.

Am J Gastroenterol. 2011 Sep;106(9):1663-9. doi: 10.1038/ajg.2011.161. Epub 2011 May 24.

PMID:
21606975
41.

The sphingosine kinase 1 and S1P1 axis specifically counteracts LPS-induced IL-12p70 production in immune cells of the spleen.

Schröder M, Richter C, Juan MH, Maltusch K, Giegold O, Quintini G, Pfeilschifter JM, Huwiler A, Radeke HH.

Mol Immunol. 2011 May;48(9-10):1139-48. doi: 10.1016/j.molimm.2011.02.007. Epub 2011 Mar 23.

PMID:
21435724
42.

CD40 ligand-triggered human dendritic cells mount interleukin-23 responses that are further enhanced by danger signals.

Sender LY, Gibbert K, Suezer Y, Radeke HH, Kalinke U, Waibler Z.

Mol Immunol. 2010 Mar;47(6):1255-61. doi: 10.1016/j.molimm.2009.12.008. Epub 2010 Jan 13.

PMID:
20071030
43.

Platelet, not endothelial, P-selectin expression contributes to generation of immunity in cutaneous contact hypersensitivity.

Ludwig RJ, Bergmann P, Garbaraviciene J, von Stebut E, Radeke HH, Gille J, Diehl S, Hardt K, Henschler R, Kaufmann R, Pfeilschifter JM, Boehncke WH.

Am J Pathol. 2010 Mar;176(3):1339-45. doi: 10.2353/ajpath.2010.081100. Epub 2010 Jan 7.

44.

Junctional adhesion molecule (JAM)-B supports lymphocyte rolling and adhesion through interaction with alpha4beta1 integrin.

Ludwig RJ, Hardt K, Hatting M, Bistrian R, Diehl S, Radeke HH, Podda M, Schön MP, Kaufmann R, Henschler R, Pfeilschifter JM, Santoso S, Boehncke WH.

Immunology. 2009 Oct;128(2):196-205. doi: 10.1111/j.1365-2567.2009.03100.x.

45.

Multivariate analyses of immune reconstitution in children after allo-SCT: risk-estimation based on age-matched leukocyte sub-populations.

Koenig M, Huenecke S, Salzmann-Manrique E, Esser R, Quaritsch R, Steinhilber D, Radeke HH, Martin H, Bader P, Klingebiel T, Schwabe D, Schneider G, Lehrnbecher T, Orth A, Koehl U.

Bone Marrow Transplant. 2010 Apr;45(4):613-21. doi: 10.1038/bmt.2009.204. Epub 2009 Aug 24.

PMID:
19701252
46.

Ncf1 provides a reactive oxygen species-independent negative feedback regulation of TLR9-induced IL-12p70 in murine dendritic cells.

Richter C, Juan MH, Will J, Brandes RP, Kalinke U, Akira S, Pfeilschifter JM, Hultqvist M, Holmdahl R, Radeke HH.

J Immunol. 2009 Apr 1;182(7):4183-91. doi: 10.4049/jimmunol.0800795.

47.

Computer-aided analysis of cell interactions under dynamic flow conditions.

Giegold O, Ludwig RJ, Hardt K, Will J, Schön MP, Oostingh GJ, Pfeilschifter JM, Boehncke WH, Radeke HH.

Exp Dermatol. 2009 Mar;18(3):238-45. doi: 10.1111/j.1600-0625.2008.00793.x. Epub 2008 Oct 22. Erratum in: Exp Dermatol. 2009 Dec;18(12):1096.

PMID:
19054063
48.

PS3, a semisynthetic beta-1,3-glucan sulfate, diminishes contact hypersensitivity responses through inhibition of L- and P-selectin functions.

Alban S, Ludwig RJ, Bendas G, Schön MP, Oostingh GJ, Radeke HH, Fritzsche J, Pfeilschifter J, Kaufmann R, Boehncke WH.

J Invest Dermatol. 2009 May;129(5):1192-202. doi: 10.1038/jid.2008.358. Epub 2008 Dec 4.

49.

Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis.

Wiesemann E, Deb M, Hemmer B, Radeke HH, Windhagen A.

Clin Immunol. 2008 Sep;128(3):306-13. doi: 10.1016/j.clim.2008.04.007. Epub 2008 Jun 9.

PMID:
18539537
50.

Posttranslational modification of the AU-rich element binding protein HuR by protein kinase Cdelta elicits angiotensin II-induced stabilization and nuclear export of cyclooxygenase 2 mRNA.

Doller A, Akool el-S, Huwiler A, Müller R, Radeke HH, Pfeilschifter J, Eberhardt W.

Mol Cell Biol. 2008 Apr;28(8):2608-25. doi: 10.1128/MCB.01530-07. Epub 2008 Feb 19.

Supplemental Content

Loading ...
Support Center